Truist assumed coverage of Perspective Therapeutics (CATX) with a Buy rating with a price target of $12, up from $8. The company is leading the next wave of radiopharmaceutical innovation, combining manufacturing readiness with cutting-edge molecular design to deliver precision oncology at scale, the analyst tells investors in a research note. Perspective’s lead program VMT-alpha-NET has a promising interim phase 1/2B profile, and additional programs in melanoma and FAP offer upside, the firm added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics price target lowered to $7 from $18 at UBS
- Buy Rating Affirmed for Perspective Therapeutics Amid Promising Developments in VMT-α-NET Program
- Perspective Therapeutics price target lowered to $11 from $12 at B. Riley
- Perspective Therapeutics Reports Q3 2025 Results and Clinical Progress
- Positive Outlook for Perspective Therapeutics Amidst Key Catalysts and Financial Resilience